CN103076453B - P16免疫细胞化学试剂盒及其制备用多肽序列 - Google Patents
P16免疫细胞化学试剂盒及其制备用多肽序列 Download PDFInfo
- Publication number
- CN103076453B CN103076453B CN201210567622.3A CN201210567622A CN103076453B CN 103076453 B CN103076453 B CN 103076453B CN 201210567622 A CN201210567622 A CN 201210567622A CN 103076453 B CN103076453 B CN 103076453B
- Authority
- CN
- China
- Prior art keywords
- antibody
- cell
- sequence
- kit
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 43
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 32
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 31
- 239000003153 chemical reaction reagent Substances 0.000 title abstract description 9
- 210000002865 immune cell Anatomy 0.000 title abstract 2
- 239000012530 fluid Substances 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 59
- 239000013558 reference substance Substances 0.000 claims description 37
- 239000008363 phosphate buffer Substances 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000013642 negative control Substances 0.000 claims description 18
- 238000003365 immunocytochemistry Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 13
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 12
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 10
- 206010041047 Slow virus infection Diseases 0.000 claims description 7
- 229930024421 Adenine Natural products 0.000 claims description 6
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- 229960000643 adenine Drugs 0.000 claims description 6
- 229940113082 thymine Drugs 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 4
- 210000003292 kidney cell Anatomy 0.000 claims description 4
- 108010005636 polypeptide C Proteins 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical group C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 238000013016 damping Methods 0.000 claims description 3
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 239000006035 Tryptophane Substances 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 229960004799 tryptophan Drugs 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 148
- 108090000623 proteins and genes Proteins 0.000 abstract description 57
- 102000004169 proteins and genes Human genes 0.000 abstract description 34
- 239000000758 substrate Substances 0.000 abstract description 23
- 201000011510 cancer Diseases 0.000 abstract description 13
- 206010028980 Neoplasm Diseases 0.000 abstract description 12
- 102000004190 Enzymes Human genes 0.000 abstract description 6
- 108090000790 Enzymes Proteins 0.000 abstract description 6
- 239000000599 controlled substance Substances 0.000 abstract 2
- 239000007853 buffer solution Substances 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000001855 preneoplastic effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- 241000699666 Mus <mouse, genus> Species 0.000 description 34
- 230000008569 process Effects 0.000 description 31
- 239000000047 product Substances 0.000 description 29
- 238000010790 dilution Methods 0.000 description 26
- 239000012895 dilution Substances 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 26
- 241000700605 Viruses Species 0.000 description 23
- 101000980932 Homo sapiens Cyclin-dependent kinase inhibitor 2A Proteins 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 22
- 102000051323 human CDKN2A Human genes 0.000 description 22
- 239000000203 mixture Substances 0.000 description 19
- 238000002372 labelling Methods 0.000 description 16
- 239000000427 antigen Substances 0.000 description 15
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 210000004408 hybridoma Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 108020004459 Small interfering RNA Proteins 0.000 description 13
- 238000001514 detection method Methods 0.000 description 12
- 238000004043 dyeing Methods 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000004806 packaging method and process Methods 0.000 description 8
- 239000012452 mother liquor Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 238000009595 pap smear Methods 0.000 description 5
- 238000004321 preservation Methods 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000010804 cDNA synthesis Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010057163 Ribonuclease III Proteins 0.000 description 3
- 102000003661 Ribonuclease III Human genes 0.000 description 3
- GRTOGORTSDXSFK-XJTZBENFSA-N ajmalicine Chemical compound C1=CC=C2C(CCN3C[C@@H]4[C@H](C)OC=C([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 GRTOGORTSDXSFK-XJTZBENFSA-N 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000009508 Cyclin-Dependent Kinase Inhibitor p16 Human genes 0.000 description 2
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108700002232 Immediate-Early Genes Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000002079 cooperative effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 238000013326 plasmid cotransfection Methods 0.000 description 2
- 229920000151 polyglycol Polymers 0.000 description 2
- 239000010695 polyglycol Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 101710150820 Cellular tumor antigen p53 Proteins 0.000 description 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000031852 maintenance of location in cell Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000012514 monoclonal antibody product Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210567622.3A CN103076453B (zh) | 2012-12-24 | 2012-12-24 | P16免疫细胞化学试剂盒及其制备用多肽序列 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210567622.3A CN103076453B (zh) | 2012-12-24 | 2012-12-24 | P16免疫细胞化学试剂盒及其制备用多肽序列 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103076453A CN103076453A (zh) | 2013-05-01 |
CN103076453B true CN103076453B (zh) | 2015-04-15 |
Family
ID=48153052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210567622.3A Active CN103076453B (zh) | 2012-12-24 | 2012-12-24 | P16免疫细胞化学试剂盒及其制备用多肽序列 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103076453B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104155167A (zh) * | 2013-05-27 | 2014-11-19 | 厦门菲尔科生物技术有限公司 | 低背景的P16-INK4a染色试剂盒及其应用方法 |
CN105001327B (zh) * | 2015-02-12 | 2019-01-08 | 福州迈新生物技术开发有限公司 | 抗p16单克隆抗体及其制备方法和应用 |
CN105223058A (zh) * | 2015-09-06 | 2016-01-06 | 江苏省人民医院 | 一种乳腺癌细胞的染色方法及其应用和染色试剂盒 |
CN105131114B (zh) * | 2015-10-26 | 2018-07-06 | 无锡傲锐东源生物科技有限公司 | 抗p16蛋白单克隆抗体杂交瘤细胞及其产生的抗p16单克隆抗体和应用 |
CN107266567B (zh) * | 2017-06-05 | 2021-06-04 | 高新 | Lcrmp4单克隆抗体及其制备方法与应用 |
CN107202888B (zh) * | 2017-07-11 | 2018-10-12 | 广州江元医疗科技有限公司 | 一种用于宫颈液基细胞的p16INK4a免疫标记显色试剂盒 |
CN108558996A (zh) * | 2018-01-11 | 2018-09-21 | 广州江元医疗科技有限公司 | 一种与p16蛋白特异性结合的单克隆抗体及其在试剂盒中的应用 |
CN110850094A (zh) * | 2019-11-22 | 2020-02-28 | 西安交通大学 | 一种免疫组化双标单染试剂盒及其使用方法和应用 |
CN114163510A (zh) * | 2021-03-24 | 2022-03-11 | 深圳市新靶向生物科技有限公司 | 一种与肝癌驱动基因突变相关的抗原肽组合及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004005927A1 (en) * | 2002-04-09 | 2004-01-15 | Mtm Laboratories Ag | Method for discrimination of metaplasias from neoplastic or preneoplastic lesions |
WO2007085958A2 (en) * | 2006-01-24 | 2007-08-02 | Consorzio Per Gli Studi Universitari In Verona | Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker |
CN101446591A (zh) * | 2008-11-15 | 2009-06-03 | 邹先进 | P16INK4a双抗体夹心酶联免疫吸附检测试剂盒 |
WO2010065968A1 (en) * | 2008-12-05 | 2010-06-10 | Myriad Genetics, Inc. | Cancer detection markers |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080280288A1 (en) * | 2004-02-06 | 2008-11-13 | Toshimitsu Uenaka | Assay Method to Predict Sensitivity of Cancer Cell to Anticancer Drug |
-
2012
- 2012-12-24 CN CN201210567622.3A patent/CN103076453B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004005927A1 (en) * | 2002-04-09 | 2004-01-15 | Mtm Laboratories Ag | Method for discrimination of metaplasias from neoplastic or preneoplastic lesions |
WO2007085958A2 (en) * | 2006-01-24 | 2007-08-02 | Consorzio Per Gli Studi Universitari In Verona | Diagnosis, prognosis and screening for medicaments for treatment of myeloproliferative disorders using receptor protein tyrosine-phosphatase gamma (ptprg) as biomarker |
CN101446591A (zh) * | 2008-11-15 | 2009-06-03 | 邹先进 | P16INK4a双抗体夹心酶联免疫吸附检测试剂盒 |
WO2010065968A1 (en) * | 2008-12-05 | 2010-06-10 | Myriad Genetics, Inc. | Cancer detection markers |
Non-Patent Citations (1)
Title |
---|
p16ink4a在宫颈病变细胞中的表达和意义;贾艳芳;《中国优秀硕士学位论文全文数据库》;20090115;第2009年卷(第1期);摘要,第3-6页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103076453A (zh) | 2013-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103076453B (zh) | P16免疫细胞化学试剂盒及其制备用多肽序列 | |
TWI831365B (zh) | 抗gpc3抗體 | |
Ferguson et al. | The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance | |
CN103408664B (zh) | 抗人cxcl1单克隆抗体或其片段 | |
EP1114322A1 (en) | Tandem immuno-assay for cancer | |
CN101074264B (zh) | 一种重组抗ctla4单克隆抗体及其制备方法和用途 | |
Trad et al. | Development of sandwich ELISA for detection and quantification of human and murine a disintegrin and metalloproteinase17 | |
CN110684740A (zh) | 一种抗人泛素羧基末端水解酶-1(uch-l1)的单克隆抗体及其应用 | |
Duex et al. | RNA interference screen identifies Usp18 as a regulator of epidermal growth factor receptor synthesis | |
EP2884277B1 (en) | Method and immunoassay reagent for measuring PIVKA-II | |
CN114044822A (zh) | 血清淀粉样蛋白a抗体的重链和轻链可变区、抗体及运用 | |
Barber et al. | Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH‐Wildtype Glioblastoma | |
CN115667304A (zh) | 抗人lag-3抗体及其在免疫组织化学(ihc)中的用途 | |
KR910002957B1 (ko) | 췌장의 α-아밀라제를 정량하는 방법 및 시약 | |
ITCH20120008A1 (it) | Uso di trop-2 come marcatore predittivo di risposta a terapia anti-tumorale basata su inibitori di cd9, akt e vie di segnale collegate | |
CN103596984A (zh) | 抗-人epo受体的抗体及使用方法 | |
Kotani et al. | Host cell membrane proteins located near SARS-CoV-2 spike protein attachment sites are identified using proximity labeling and proteomic analysis | |
CN112646036B (zh) | 一种抗cd23特异性单克隆抗体及其应用 | |
Jin et al. | LRMP associates with immune infiltrates and acts as a prognostic biomarker in lung adenocarcinoma | |
IT202000031838A1 (it) | Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici | |
CN101074263B (zh) | 一种重组抗proteinA单克隆抗体及其制备方法和用途 | |
Hand et al. | Absolute values of ras p21 defined by direct binding liquid competition radioimmunoassays | |
Langellotti et al. | A novel anti-aldolase C antibody specifically interacts with residues 85–102 of the protein | |
JPH0412273A (ja) | 細胞の増殖能測定方法 | |
Schofield et al. | Sequencing and affinity determination of antigen-specific B lymphocytes from peripheral blood |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160328 Address after: 200030, room 900, 805 Yu Chi Road, Shanghai, Xuhui District Patentee after: He Yifeng Patentee after: Di Wen Patentee after: SHANGHAI TOPGEN BIOMEDICAL TECHNOLOGY CO.,LTD. Address before: 200030, room 900, 805 Yu Chi Road, Shanghai, Xuhui District Patentee before: He Yifeng Patentee before: Di Wen |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170930 Address after: 200030 room 900, 805, Panyu Road, Shanghai, Xuhui District Co-patentee after: SHANGHAI TOPGEN BIOMEDICAL TECHNOLOGY CO.,LTD. Patentee after: He Yifeng Address before: 200030, room 900, 805 Yu Chi Road, Shanghai, Xuhui District Co-patentee before: Di Wen Patentee before: He Yifeng Co-patentee before: SHANGHAI TOPGEN BIOMEDICAL TECHNOLOGY CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211021 Address after: Room 805, no.900 Panyu Road, Xuhui District, Shanghai 200030 Patentee after: He Yifeng Address before: Room 805, no.900 Panyu Road, Xuhui District, Shanghai 200030 Patentee before: He Yifeng Patentee before: SHANGHAI TOPGEN BIOMEDICAL TECHNOLOGY Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211122 Address after: Room 805, no.900 Panyu Road, Xuhui District, Shanghai 200030 Patentee after: He Yifeng Patentee after: Henan Guanyi Medical Technology Co.,Ltd. Address before: Room 805, no.900 Panyu Road, Xuhui District, Shanghai 200030 Patentee before: He Yifeng |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240109 Address after: Room 805, no.900 Panyu Road, Xuhui District, Shanghai 200030 Patentee after: He Yifeng Address before: Room 805, no.900 Panyu Road, Xuhui District, Shanghai 200030 Patentee before: He Yifeng Patentee before: Henan Guanyi Medical Technology Co.,Ltd. |